Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Dr. Awan on Treatment Options in the First Relapsed Setting of CLL

October 23rd 2020

Farrukh Awan, MD, discusses treatment options in the first relapsed setting in patients with chronic lymphocytic leukemia.

Dr. Skarbnik on Treatment Considerations in CLL

October 22nd 2020

Alan P. Z. Skarbnik, MD, discusses treatment considerations in chronic lymphocytic leukemia.

TP53 Mutations Among Prognostic Factors Associated With Ibrutinib-Resistant CLL

October 21st 2020

Patients with chronic lymphocytic leukemia who are at an increased risk of failure on ibrutinib can be identified prior to treatment initiation using a 4-factor prognostic model and considered for a clinical trial.

Dr. Bhat on ELEVATE-TN Results in Treatment-Naïve CLL

October 21st 2020

Seema A. Bhat, MD, discusses the results of the phase 3 ELEVATE-TN trial in patients with treatment-naïve CLL.

FDA Grants Ublituximab/Umbralisib Combo Fast Track Status in CLL

October 21st 2020

The FDA has granted a fast track designation to the investigational CD20-directed monoclonal antibody ublituximab in combination with the PI3K-delta inhibitor umbralisib for the treatment of adult patients with chronic lymphocytic leukemia.

Dr. Skarbnik on Frontline Treatment Considerations in CLL

October 20th 2020

Alan P. Z. Skarbnik, MD, discusses frontline treatment considerations in chronic lymphocytic leukemia.

Dr. Bhat on the FDA Approval of Acalabrutinib in CLL

October 19th 2020

Seema A. Bhat, MD, discusses the approval of acalabrutinib in chronic lymphocytic leukemia based on data from the phase 3 ELEVATE-TN trial.

Dr. Bhat on the Potential for Time-Limited Combinations in CLL

October 15th 2020

Seema A. Bhat, MD, discusses the potential for time-limited combination regimens in chronic lymphocytic leukemia.

Dr. Ma on Developing Novel Agents in BTK Inhibitor–Resistant CLL

October 15th 2020

Shuo Ma, MD, PhD, discusses the need to develop novel agents to treat patients with chronic lymphocytic leukemia who develop resistance to BTK inhibitors.

Dr. Davids on Investigational Doublets and Triplets in CLL

October 15th 2020

Matthew S. Davids, MD, MMSc, discusses investigational doublets and triplets in chronic lymphocytic leukemia.

Targeted Therapies Take Center Stage in the CLL Treatment Paradigm

October 14th 2020

Seema A. Bhat, MD, spotlights the advances that have been made with BTK inhibitors in chronic lymphocytic leukemia, shares emerging approaches under exploration, and forecasts where the field is headed.

Dr. Bhat on Emerging Targeted Therapies in CLL

October 14th 2020

Seema A. Bhat, MD, emerging targeted therapies in chronic lymphocytic leukemia.

Novel Approaches Lead the Charge Away from Chemoimmunotherapy in CLL

October 14th 2020

Matthew S. Davids, MD, MMSc, discusses the shift away from chemoimmunotherapy in chronic lymphocytic leukemia and ongoing research in the space.

Research Efforts Abound as the Role of BTK Inhibitors Continues to Evolve in CLL

October 14th 2020

Erlene  Seymour, MD, discusses BTK inhibitors and how they have shifted the standard of care for the frontline treatment of patients with chronic lymphocytic leukemia.

Dr. Davids on Selecting Between Continuous and Time-Limited Therapy in CLL

October 13th 2020

Matthew S. Davids, MD, MMSc, discusses selecting between continuous and time-limited therapy in chronic lymphocytic leukemia.

Venetoclax/Rituximab Maintains PFS Advantage With uMRD in Relapsed/Refractory CLL

October 13th 2020

A fixed-duration of venetoclax plus rituximab led to sustained and durable responses in patients with relapsed/refractory chronic lymphocytic leukemia who achieved undetectable minimal residual disease.

Dr. Bhat on the Rationale to Evaluate Acalabrutinib in CLL

October 12th 2020

Seema A. Bhat, MD, discusses the rationale to evaluate acalabrutinib in chronic lymphocytic leukemia.

Dr. Davids on Factors to Inform Treatment Selection in CLL

October 9th 2020

Matthew S. Davids, MD, MMSc, discusses factors to consider when selecting treatment for patients with chronic lymphocytic leukemia.

Dr. Pleyer on Next Steps With Ibrutinib Plus Short-Course Fludarabine in Previously Untreated CLL

October 8th 2020

Christopher Pleyer, MD, discusses the next steps with the combination of ibrutinib and short-course fludarabine in previously untreated chronic lymphocytic leukemia.

Dr. Pleyer on Remaining Questions With Ibrutinib Plus Short-Course Fludarabine in CLL

October 8th 2020

Christopher Pleyer, MD, discusses the safety and effectiveness of ibrutinib plus short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.